EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Tolerance Induction Strategies in Organ Transplantation: Current Status and Future Perspectives

Tifanie Blein, Nicolas Ayas, Soëli Charbonnier, Artur Gil, Juliette Leon, Julien Zuber

Transplant International · 2025

DOI: 10.3389/ti.2025.14958 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Transplant International, 2025. Verfasst von Tifanie Blein und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institut Necker Enfant Malades, Institut national de la santé et de la recherche médicale (INSERM) Unité U1151, Paris, France. Hauptthemen laut MEDLINE: Organ Transplantation, Transplantation Tolerance, Immune Tolerance. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Achieving donor-specific immune tolerance has the potential to eliminate the need for lifelong immunosuppression in transplant recipients, but translating this goal into clinical practice remains challenging. Unlike laboratory rodents, humans are exposed to a variety of pathogens that generate memory T cells, which can interfere with tolerance induction. Establishing full donor hematopoietic chimerism, whether spontaneous or induced, can support robust immune tolerance. However, it often relies on graft-versus-host (GvH) reactivity, which carries significant risks, including graft-versus-host disease (GVHD) and infection. Although non-myeloablative conditioning protocols have shown promise, their broader use is limited by concerns about toxicity and the need to carefully balance GvH responses. Mixed and transient chimerism represents a less toxic alternative, but its effectiveness in humans is hindered by limited durability and resistance from memory T cells. Thymus transplantation offers another strategy by promoting central tolerance through donor-specific thymic education of developing T cells. Regulatory cell therapies combined with reduced immunosuppression have emerged as a safer approach. Early clinical trials have yielded encouraging results. Innovations in IL-2 pathway modulation and genetic engineering, including CAR-redirected regulatory T cells, may further enhance the precision, durability, and safety of strategies aimed at achieving transplantation tolerance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Organ TransplantationTransplantation ToleranceImmune ToleranceHumansAnimalsTransplantation ConditioningT-Lymphocytes, RegulatoryGraft vs Host DiseaseThymus GlandImmunosuppression Therapy

Stichwörter der Autor:innen

genetic engineeringhematopoietic chimerismimmune tolerance inductionregulatory cell therapythymustransplantation

Autor:innen und Institutionen

  • Institut Necker Enfant Malades, Institut national de la santé et de la recherche médicale (INSERM) Unité U1151, Paris, France.
  • Université Paris Cité, Paris, France.
  • Service des Maladies du Rein et du Métabolisme, Transplantation et Immunologie Clinique, Hôpital Necker, Assistance Publique Hôpitaux de Paris (APHP), Paris, France.

Zitieren

APA

Blein, T., Ayas, N., Charbonnier, S., Gil, A., Leon, J., & Zuber, J. (2025). Tolerance Induction Strategies in Organ Transplantation: Current Status and Future Perspectives. Transplant International. https://doi.org/10.3389/ti.2025.14958

Vancouver

Blein T, Ayas N, Charbonnier S, Gil A, Leon J, Zuber J. Tolerance Induction Strategies in Organ Transplantation: Current Status and Future Perspectives. Transplant International. 2025. doi:10.3389/ti.2025.14958

BibTeX
@article{Blein2025,
  author = {Blein, Tifanie and Ayas, Nicolas and Charbonnier, Soëli and Gil, Artur and Leon, Juliette and Zuber, Julien},
  title = {Tolerance Induction Strategies in Organ Transplantation: Current Status and Future Perspectives},
  journal = {Transplant International},
  year = {2025},
  doi = {10.3389/ti.2025.14958}
}
Kostenlos starten →